Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  HIV Infection

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 111 articles:
HTML format
Text format



Single Articles


    August 2018
  1. SPIVAK AM, Nell RA, Petersen M, Martins L, et al
    Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.
    Antimicrob Agents Chemother. 2018 Aug 13. pii: AAC.01361.
    PubMed     Text format     Abstract available


  2. INNES S, van der Laan L, Anderson PL, Cotton M, et al
    CAN WE IMPROVE STAVUDINE'S SAFETY PROFILE IN CHILDREN? PHARMACOKINETICS OF INTRACELLULAR STAVUDINE-TRIPHOSPHATE WITH REDUCED-DOSING.
    Antimicrob Agents Chemother. 2018 Aug 13. pii: AAC.00761.
    PubMed     Text format     Abstract available


  3. KANDLER JL, Mercante AD, Dalton TL, Ezewudo MN, et al
    Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests.
    Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.00974.
    PubMed     Text format     Abstract available


  4. ADEGBOLA A, Abutaima R, Olagunju A, Ijarotimi O, et al
    Effect of pregnancy on the pharmacokinetic interaction between efavirenz and lumefantrine in HIV-malaria co-infection.
    Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.01252.
    PubMed     Text format     Abstract available


  5. DOOKIE N, Naidoo K, Padayatchi N
    Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2018;62.
    PubMed     Text format    


    July 2018
  6. MILLER JT, Zhao H, Masaoka T, Varnado B, et al
    Sensitivity of the C-terminal nuclease domain of Kaposi's sarcoma-associated herpesvirus ORF29 to two classes of active site ligands.
    Antimicrob Agents Chemother. 2018 Jul 30. pii: AAC.00233.
    PubMed     Text format     Abstract available


  7. SMITH RA, Wu VH, Zavala CG, Raugi DN, et al
    In vitro antiviral activity of cabotegravir against HIV-2.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.01299.
    PubMed     Text format     Abstract available


  8. BARRETT SE, Teller RS, Forster SP, Li L, et al
    Extended Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.01058.
    PubMed     Text format     Abstract available


  9. KANWAR A, Cadnum JL, Jencson AL, Donskey CJ, et al
    Impact of Antibiotic Treatment on the Burden of Nasal Staphylococcus aureus Among Hospitalized Patients.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00609.
    PubMed     Text format     Abstract available


  10. SMITH SJ, Zhao XZ, Burke TR Jr, Hughes SH, et al
    HIV-1 integrase inhibitors that are broadly effective against drug-resistant mutants.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.01035.
    PubMed     Text format     Abstract available


  11. MEHTA R, Wolstenholme A, Di Lullo K, Fu C, et al
    Bioequivalence of a Fixed-Dose Combination Tablet of the Complete 2-Drug Regimen Dolutegravir and Rilpivirine for the Treatment of HIV-1 Infection.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.00748.
    PubMed     Text format     Abstract available


    June 2018
  12. ANKROM W, Yee KL, Sanchez RI, Adedoyin A, et al
    Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.
    Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00326.
    PubMed     Text format     Abstract available


    May 2018
  13. SPADARI CC, Vila T, Rozental S, Ishida K, et al
    Miltefosine has post-antifungal effect and induces apoptosis in Cryptococcus yeasts.
    Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00312.
    PubMed     Text format     Abstract available


  14. BANDA CG, Dzinjalamala F, Mukaka M, Mallewa J, et al
    Pharmacokinetics of piperaquine and safety profile of dihydroartemisinin-piperaquine co-administered with antiretroviral therapy in malaria-uninfected HIV-positive Malawian adults.
    Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00634.
    PubMed     Text format     Abstract available


  15. YEW WW, Chang KC, Chan DP
    Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.
    Antimicrob Agents Chemother. 2018 May 21. pii: AAC.02637.
    PubMed     Text format     Abstract available


  16. BANDA CG, Dzinjalamala F, Mukaka M, Mallewa J, et al
    Pharmacokinetics and safety profile of artesunate-amodiaquine co-administered with antiretroviral therapy in malaria uninfected HIV-positive Malawian adults.
    Antimicrob Agents Chemother. 2018 May 14. pii: AAC.00412.
    PubMed     Text format     Abstract available


  17. FOCA E, Calcagno A, Bonito A, Cusato J, et al
    Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir.
    Antimicrob Agents Chemother. 2018 May 14. pii: AAC.00309.
    PubMed     Text format     Abstract available


  18. AMMERMAN NC, Swanson RV, Bautista EM, Almeida DV, et al
    Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
    Antimicrob Agents Chemother. 2018 May 7. pii: AAC.00636.
    PubMed     Text format     Abstract available


    April 2018
  19. STADER F, Kinvig H, Battegay M, Khoo S, et al
    Analysis of clinical drug-drug interaction data to predict uncharacterized interaction magnitudes between antiretroviral drugs and co-medications.
    Antimicrob Agents Chemother. 2018 Apr 23. pii: AAC.00717.
    PubMed     Text format     Abstract available


  20. MOURE R, Domingo P, Villarroya J, Gasa L, et al
    Reciprocal effects of antiretroviral drugs used to treat HIV infection on the fibroblast growth factor-21/beta-Klotho system.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00029.
    PubMed     Text format     Abstract available


    March 2018
  21. ENOSI TUIPULOTU D, Netzler NE, Lun JH, Mackenzie JM, et al
    TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation.
    Antimicrob Agents Chemother. 2018 Mar 12. pii: AAC.02417.
    PubMed     Text format     Abstract available


    February 2018
  22. LE HN, Quetz JS, Tran VG, Le VTM, et al
    MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model.
    Antimicrob Agents Chemother. 2018 Feb 26. pii: AAC.02565.
    PubMed     Text format     Abstract available


  23. DELINO NS, Aoki M, Hayashi H, Hattori SI, et al
    GRL-079, a novel P2-Tp-THF-C5-alkylamine- and P2' -Abt-containing HIV-1 protease inhibitor, is extremely potent against multi-drug-resistant HIV-1 variants including HIVDRV(R)p51 and has a high genetic barrier against the emergence of resistant varian
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02060.
    PubMed     Text format     Abstract available


    January 2018
  24. UCHIYA KI, Asahi S, Futamura K, Hamaura H, et al
    Antibiotic susceptibility and genotyping of Mycobacterium avium strains that cause pulmonary and disseminated infection.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02035.
    PubMed     Text format     Abstract available


    November 2017
  25. KAKADIYA PP, Higginson RT, Fulco PP
    Ritonavir-boosted protease inhibitors but not cobicistat appear safe in HIV-positive patients ingesting dabigatran.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.02275.
    PubMed     Text format     Abstract available


  26. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
    Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
    PubMed     Text format     Abstract available


  27. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
    Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
    PubMed     Text format     Abstract available


    October 2017
  28. XIAO P, Gumber S, Marzinke MA, Date AA, et al
    Hypo-osmolar formulation of TFV enema promotes uptake and metabolism of TFV in tissues and leading to prevention of SHIV/SIV infection.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01644.
    PubMed     Text format     Abstract available


  29. HERRERO-FERNANDEZ I, Pacheco YM, Genebat M, Rodriguez-Mendez MDM, et al
    Association between a suppressor combined antiretroviral therapy containing Maraviroc and the hepatitis B virus vaccine response.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.02050.
    PubMed     Text format     Abstract available


  30. HEALAN AM, Griffiss JM, Proskin HM, O'Riordan MA, et al
    Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics: A Randomized Clinical Trial in Healthy Adult Volunteers.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.00855.
    PubMed     Text format     Abstract available


  31. ANDERSON PL, Liu AY, Castillo-Mancilla JR, Gardner EM, et al
    Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.
    Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01710.
    PubMed     Text format     Abstract available


  32. SERRANO-VILLAR S, Caruana G, Zlotnik A, Perez-Molina JA, et al
    The effects of maraviroc versus efavirenz in combination with zidovudine/lamivudine on the CD4/CD8 ratio in treatment-naive HIV-infected individuals.
    Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01763.
    PubMed     Text format     Abstract available


    September 2017
  33. ELOY P, Tessier A, Fan-Havard P, Chou M, et al
    Genetics of nevirapine metabolic pathways at steady state in HIV-infected Cambodians.
    Antimicrob Agents Chemother. 2017 Sep 25. pii: AAC.00733.
    PubMed     Text format     Abstract available


  34. HASSOUNAH SA, Alikhani A, Oliveira M, Bharaj S, et al
    Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1.
    Antimicrob Agents Chemother. 2017 Sep 18. pii: AAC.01695.
    PubMed     Text format     Abstract available


  35. PATEL S, Leibrand CR, Palasuberniam P, Couraud PO, et al
    Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function In Vitro.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01307.
    PubMed     Text format     Abstract available


  36. ZHAO N, Wang G, Das AT, Berkhout B, et al
    Combinatorial CRISPR-Cas9 and RNAi attack on HIV-1 DNA and RNA can lead to cross-resistance.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01486.
    PubMed     Text format     Abstract available


  37. KOSAKA M, Ushiki A, Ikuyama Y, Hirai K, et al
    Efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia in patients without human immunodeficiency virus infection: A four-center retrospective study.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01173.
    PubMed     Text format     Abstract available


  38. GARCIA-VIDAL E, Castellvi M, Pujantell M, Badia R, et al
    Evaluation of the innate immune modulator acitretin as a strategy to clear the HIV reservoir.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01368.
    PubMed     Text format     Abstract available


    August 2017
  39. CHATTERJEE SS, Chen L, Gilbert A, da Costa TM, et al
    PBP4 mediates beta-lactam resistance by altered function.
    Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.00932.
    PubMed     Text format     Abstract available


  40. MCBRIDE JW, Dias N, Cameron D, Offord RE, et al
    Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration.
    Antimicrob Agents Chemother. 2017 Aug 7. pii: AAC.00965.
    PubMed     Text format     Abstract available


    July 2017
  41. KIRBY KA, Myshakina NA, Christen MT, Chen YL, et al
    A 2-hydroxyisoquinoline-1,3-dione active site RNase H inhibitor binds in multiple modes to HIV-1 reverse transcriptase.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01351.
    PubMed     Text format     Abstract available


  42. FORD SL, Sutton K, Lou Y, Zhang Z, et al
    Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00487.
    PubMed     Text format     Abstract available


  43. REZNICEK J, Ceckova M, Ptackova Z, Martinec O, et al
    MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir; effect on intestinal absorption.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00837.
    PubMed     Text format     Abstract available


    June 2017
  44. CHAN CN, Trinite B, Levy DN
    Potent inhibition of HIV-1 replication in resting CD4 T cells by resveratrol and pterostilbene.
    Antimicrob Agents Chemother. 2017 Jun 26. pii: AAC.00408.
    PubMed     Text format     Abstract available


  45. CHIREHWA MT, McIlleron H, Rustomjee R, Mthiyane T, et al
    Pharmacokinetics of Pyrazinamide: optimising dosing regimens for drug-sensitive and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00490.
    PubMed     Text format     Abstract available


  46. WENSEL D, Sun Y, Li Z, Zhang S, et al
    Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00508.
    PubMed     Text format     Abstract available


  47. FOLI Y, Ghebremichael M, Li M, Paintsil E, et al
    Upregulation of Apoptosis Pathway Genes in Peripheral Blood Mononuclear Cells of HIV-Infected Individuals with Antiretroviral Therapy-Associated Mitochondrial Toxicity.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00522.
    PubMed     Text format     Abstract available


    May 2017
  48. HABTEWOLD A, Aklillu E, Makonnen E, Yimer G, et al
    Population pharmacokinetic model linking plasma and peripheral blood mononuclear cells (PBMCs) concentrations of efavirenz and its metabolite, 8-hydroxy-efavirenz in HIV patients.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00207.
    PubMed     Text format     Abstract available


  49. ROSADO-SANCHEZ I, Herrero-Fernandez I, Alvarez-Rios AI, Genebat M, et al
    A lower baseline CD4/CD8 T-cell ratio is independently associated with immunodiscordant response to antiretroviral therapy in HIV-infected subjects.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00605.
    PubMed     Text format     Abstract available


  50. WU VH, Smith RA, Masoum S, Raugi DN, et al
    MK-8591 (4' -ethynyl-2-fluoro-2' -deoxyadenosine) exhibits potent activity against HIV-2 isolates and drug-resistant HIV-2 mutants in culture.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00744.
    PubMed     Text format     Abstract available


  51. FLETA-SORIANO E, Smutna K, Martinez JP, Lorca Oro C, et al
    The myxobacterial metabolite Soraphen A inhibits HIV-1 by reducing virus production and altering virion composition.
    Antimicrob Agents Chemother. 2017 May 22. pii: AAC.00739.
    PubMed     Text format     Abstract available


  52. HACHIYA A, Kirby KA, Ido Y, Shigemi U, et al
    Impact of HIV-1 Integrase L74F/V75I Mutations from a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
    Antimicrob Agents Chemother. 2017 May 22. pii: AAC.00315.
    PubMed     Text format     Abstract available


  53. STEENS JM, Scherrer D, Gineste P, Barrett PN, et al
    Safety, Pharmacokinetics and_Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment- Naive HIV Infected Subjects: a Phase II Randomized, Controlled Study.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00545.
    PubMed     Text format     Abstract available


  54. GIACOBBI NS, Sluis-Cremer N
    In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine and MIV-150: NNRTI Microbicides in Clinical Development for the Prevention of HIV-1 Infection.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00277.
    PubMed     Text format     Abstract available


  55. PRESSIAT C, Amorissani-Folquet M, Yonaba C, Treluyer JM, et al
    Pharmacokinetics of Efavirenz in 2-3 years old children: a high dose of 25 mg/kg per day.
    Antimicrob Agents Chemother. 2017 May 8. pii: AAC.00297.
    PubMed     Text format     Abstract available


    April 2017
  56. ZHANG Y, Clarke W, Marzinke MA, Piwowar-Manning E, et al
    Evaluation of a multi-drug assay for monitoring adherence to a regimen for HIV pre-exposure prophylaxis in a clinical study (HIV Prevention Trials Network 073).
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.02743.
    PubMed     Text format     Abstract available


  57. NAKAMURA RL, Burlingame MA, Yang S, Crosby DC, et al
    Identification and optimization of thienopyridine carboxamides as inhibitors of HIV regulatory complexes.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02366.
    PubMed     Text format     Abstract available


  58. ZHAO C, Gunawardana M, Villinger F, Baum MM, et al
    Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02465.
    PubMed     Text format     Abstract available


  59. DAS K, Martinez SE, Arnold E
    Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex that Confer Multi-Nucleoside Drug Resistance.
    Antimicrob Agents Chemother. 2017 Apr 10. pii: AAC.00224.
    PubMed     Text format     Abstract available


    March 2017
  60. RIMAWI BH, Johnson E, Rajakumar A, Tao S, et al
    Pharmacokinetics and Placental Transfer of Elvitegravir and Dolutegravir, and Other Antiretrovirals during Pregnancy.
    Antimicrob Agents Chemother. 2017 Mar 27. pii: AAC.02213.
    PubMed     Text format     Abstract available


  61. HUBER AD, Michailidis E, Tang J, Puray-Chavez MN, et al
    3-hydroxypyrimidine-2,4-diones as novel hepatitis B virus antivirals targeting the viral ribonuclease H.
    Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00245.
    PubMed     Text format     Abstract available


  62. MOYA B, Barcelo IM, Bhagwat S, Patel M, et al
    WCK 5107 (Zidebactam) & WCK 5153: Novel inhibitors of PBP2 showing potent "beta-lactam enhancer" activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-beta-lactamase-producing high-risk clones.
    Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02529.
    PubMed     Text format     Abstract available


  63. NIGO M, Diaz L, Carvajal LP, Tran TT, et al
    Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available


    February 2017
  64. VIDYAPRAKASH E, Abrams AJ, Shafer WM, Trees DL, et al
    Whole genome sequencing of a large panel of contemporary Neisseria gonorrhoeae clinical isolates indicates that a wild-type mtrA gene is common: implications for inducible antimicrobial resistance.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.00262.
    PubMed     Text format     Abstract available


  65. KOUTSOUDAKIS G, Paris de Leon A, Herrera C, Dorner M, et al
    Oligonucleotide-lipid conjugates forming G-quadruplex structures are potent and pangenotypic hepatitis C virus entry inhibitors in vitro and ex vivo.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02354.
    PubMed     Text format     Abstract available


  66. ROBERTS O, Khoo S, Owen A, Siccardi M, et al
    Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat In Vitro.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.01776.
    PubMed     Text format     Abstract available


  67. CHOI SR, Britigan BE, Narayanasamy P
    Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
    PubMed     Text format     Abstract available


    January 2017
  68. LE VT, Le HN, Pinheiro MG, Hahn KJ, et al
    Effects of tedizolid phosphate on survival outcomes and suppression of production of staphylococcal toxins in a rabbit model of MRSA necrotizing pneumonia.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02734.
    PubMed     Text format     Abstract available


  69. DIEP BA, Hillard JJ, Le VT, Tkaczyk C, et al
    Targeting Alpha Toxin to Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.
    Antimicrob Agents Chemother. 2017 Jan 23. pii: AAC.02456.
    PubMed     Text format     Abstract available


  70. GOMARASCA M, Martins TF, Greune L, Hardwidge PR, et al
    Bacterial-derived cell-penetrating peptides deliver gentamicin to kill intracellular pathogens.
    Antimicrob Agents Chemother. 2017 Jan 17. pii: AAC.02545.
    PubMed     Text format     Abstract available


    December 2016
  71. GROSSMAN NT, Casadevall A
    Physiological Differences in C. neoformans in vitro versus in vivo and Their Effects on Antifungal Susceptibility.
    Antimicrob Agents Chemother. 2016 Dec 28. pii: AAC.02108.
    PubMed     Text format     Abstract available


  72. ZERBATO JM, Tachedjian G, Sluis-Cremer N
    Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Virus Production from Latently Infected Resting CD4+ T Cells Following Latency Reversal.
    Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.01736.
    PubMed     Text format     Abstract available


  73. LOMONOSOVA E, Zlotnick A, Tavis JE
    Synergistic Interactions between Hepatitis B Virus Ribonuclease H Antagonists and Other Inhibitors.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.02441.
    PubMed     Text format     Abstract available


  74. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
    Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
    PubMed     Text format     Abstract available


  75. VALADE E, Bouazza N, Lui G, Martinez Illamola S, et al
    Population Pharmacokinetic Modeling of Tenofovir in the Male Genital Tract of HIV-infected Patients.
    Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.02062.
    PubMed     Text format     Abstract available


  76. KING JR, Khatri A, Trinh R, Viani RM, et al
    Pharmacokinetic Evaluation of Darunavir Administered Once or Twice daily in Combination with Ritonavir or the Three Direct Acting Antiviral Regimen of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir in Adults Co-infected with Hepatitis C and Human I
    Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02135.
    PubMed     Text format     Abstract available


    November 2016
  77. FOISSAC F, Blume J, Treluyer JM, Tylleskar T, et al
    Are Prophylactic and Therapeutic Target Concentrations Different? The Case of Lopinavir/ritonavir or Lamivudine Administered to Infants for the Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01869.
    PubMed     Text format     Abstract available


  78. PENROSE KJ, Wallis CL, Brumme CJ, Hamanishi KA, et al
    Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals on Failing First-Line Antiretroviral Therapy in South Africa.
    Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01805.
    PubMed     Text format     Abstract available


  79. KHALILIEH S, Yee KL, Sanchez RI, Triantafyllou I, et al
    Results of a doravirine-atorvastatin drug-drug interaction study.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.01364.
    PubMed     Text format     Abstract available


  80. YEE KL, Sanchez RI, Auger P, Liu R, et al
    An Evaluation of Doravirine Pharmacokinetics When Switching From Efavirenz to Doravirine in Healthy Subjects.
    Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.01757.
    PubMed     Text format     Abstract available


  81. PONCE CA, Chabe M, George C, Cardenas A, et al
    High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with first episode of Pneumocystis pneumonia in Santiago, Chile, and their clinical response to trimethoprim-sulfamethoxazole therapy.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01290.
    PubMed     Text format     Abstract available


  82. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
    Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
    Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
    PubMed     Text format     Abstract available


  83. MANDAL S, Belshan M, Holec A, Zhou Y, et al
    An enhanced Emtricitabine loaded long-acting nano-formulation for prevention or treatment of HIV infection.
    Antimicrob Agents Chemother. 2016 Nov 7. pii: AAC.01475.
    PubMed     Text format     Abstract available


  84. SONOIKI E, Nsanzabana C, Legac J, Sindhe KM, et al
    Altered Plasmodium falciparum sensitivity to the antiretroviral protease inhibitor lopinavir associated with polymorphisms in pfmdr1.
    Antimicrob Agents Chemother. 2016 Nov 7. pii: AAC.01949.
    PubMed     Text format     Abstract available


    October 2016
  85. BAM RA, Hansen D, Irrinki A, Mulato A, et al
    TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.01369.
    PubMed     Text format     Abstract available


  86. AOURI M, Barcelo C, Guidi M, Rotger M, et al
    Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.00899.
    PubMed     Text format     Abstract available


  87. ROBARGE JD, Metzger IF, Lu J, Thong N, et al
    Population pharmacokinetic modeling to estimate the contribution of genetic and non-genetic factors of efavirenz disposition.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.01813.
    PubMed     Text format     Abstract available


  88. SCHERRER D, Rouzier R, Cardona M, Barrett PN, et al
    Food effect on pharmacokinetic parameters of ABX464 administered orally: a randomized trial in healthy male subjects.
    Antimicrob Agents Chemother. 2016 Oct 31. pii: AAC.01288.
    PubMed     Text format     Abstract available


    September 2016
  89. TSIANG M, Jones GS, Goldsmith J, Mulato A, et al
    Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Antimicrob Agents Chemother. 2016 Sep 19. pii: AAC.01474.
    PubMed     Text format     Abstract available


  90. FENAUX M, Lin X, Yokokawa F, Sweeney Z, et al
    Anti-viral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive for increased in vivo mitochondrial toxicity risk.
    Antimicrob Agents Chemother. 2016 Sep 19. pii: AAC.01253.
    PubMed     Text format     Abstract available


  91. AMANO M, Salcedo-Gomez PM, Zhao R, Yedidi RS, et al
    A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Antimicrob Agents Chemother. 2016 Sep 12. pii: AAC.01428.
    PubMed     Text format     Abstract available


  92. DESTA Z, Metzger IF, Thong N, Lu JB, et al
    Inhibition of CYP2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
    Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.01000.
    PubMed     Text format     Abstract available


    August 2016
  93. CASTILLO-MANCILLA J, Seifert S, Campbell K, Coleman S, et al
    Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Antimicrob Agents Chemother. 2016 Aug 29. pii: AAC.01017.
    PubMed     Text format     Abstract available


  94. GROOMS TN, Vuong HR, Tyo KM, Malik DA, et al
    Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold to Prevent HIV Infection.
    Antimicrob Agents Chemother. 2016 Aug 22. pii: AAC.00956.
    PubMed     Text format     Abstract available


  95. DIEP BA, Le VT, Visram ZC, Rouha H, et al
    Improved protection in a rabbit model of CA-MRSA necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin.
    Antimicrob Agents Chemother. 2016 Aug 15. pii: AAC.01213.
    PubMed     Text format     Abstract available


  96. KHATRI A, Trinh R, Zhao W, Podsadecki T, et al
    Drug-Drug Interaction Between the Direct-acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir and the HIV Antiretroviral Agents Dolutegravir or Abacavir Plus Lamivudine.
    Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.00795.
    PubMed     Text format     Abstract available


  97. ROCKWOOD NN, Meintjes G, Chirehwa M, Wiesner L, et al
    HIV-1 co-infection does not reduce exposure to rifampicin, isoniazid, and pyrazinamide in South African tuberculosis outpatients.
    Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.00480.
    PubMed     Text format     Abstract available


  98. GONZALEZ-SERNA A, Genebat M, De Luna-Romero M, Tarancon-Diez L, et al
    Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-term Maraviroc Monotherapy Exposure.
    Antimicrob Agents Chemother. 2016 Aug 1. pii: AAC.01326.
    PubMed     Text format     Abstract available


    July 2016
  99. MARTINEZ ZS, Castro E, Seong CS, Ceron MR, et al
    Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
    Antimicrob Agents Chemother. 2016 Jul 18. pii: AAC.00341.
    PubMed     Text format     Abstract available


  100. LE VT, Tkaczyk C, Chau S, Rao RL, et al
    Acute bacterial skin and skin structure infection: Critical role of alpha-toxin and protective effects of its neutralization by a human antibody.
    Antimicrob Agents Chemother. 2016 Jul 11. pii: AAC.00710.
    PubMed     Text format     Abstract available


  101. CECKOVA M, Reznicek J, Ptackova Z, Cerveny L, et al
    Interaction of lamivudine with ABC and SLC transporters: role in placental transport.
    Antimicrob Agents Chemother. 2016 Jul 11. pii: AAC.00648.
    PubMed     Text format     Abstract available


  102. NOGUCHI LM, Montgomery ET, Biggio JR, Hendrix CW, et al
    Detectable tenofovir levels in breastfeeding infants of mothers exposed to topical tenofovir.
    Antimicrob Agents Chemother. 2016 Jul 11. pii: AAC.00645.
    PubMed     Text format     Abstract available


  103. LI M, Mislak AC, Foli Y, Agbosu E, et al
    DNA Polymerase-gamma R953C Mutant is Associated with ART-Induced Mitochondrial Toxicity.
    Antimicrob Agents Chemother. 2016 Jul 5. pii: AAC.00976.
    PubMed     Text format     Abstract available


  104. VILLEGAS G, Calenda G, Zhang S, Mizenina O, et al
    In vitro exposure to PC-1005 and cervicovaginal lavages from women vaginally administered PC-1005 inhibit HIV-1 and HSV-2 infection in human cervical mucosa.
    Antimicrob Agents Chemother. 2016 Jul 5. pii: AAC.00392.
    PubMed     Text format     Abstract available


    June 2016
  105. LU Y, Goti V, Chaturvedula A, Haberer JE, et al
    Population pharmacokinetics of tenofovir in HIV-1 uninfected members of sero-discordant couples and effect of dose reporting methods.
    Antimicrob Agents Chemother. 2016 Jun 27. pii: AAC.00559.
    PubMed     Text format     Abstract available


  106. CHEN X, Castillo-Mancilla JR, Seifert SM, McAllister K, et al
    Analysis of the endogenous deoxynucleoside triphosphate pool in HIV positive and negative individuals receiving tenofovir-emtricitabine.
    Antimicrob Agents Chemother. 2016 Jun 27. pii: AAC.01019.
    PubMed     Text format     Abstract available


    May 2016
  107. RIVERO-BUCETA E, Sun L, Gualda BM, Doyaguez EG, et al
    An unexpected twist: optimization of a class of tryptophan dendrimers that inhibit HIV replication leads to a selective, specific and low nanomolar inhibitor of clinical isolates of enterovirus A71.
    Antimicrob Agents Chemother. 2016 May 31. pii: AAC.00626.
    PubMed     Text format     Abstract available


  108. CUSTODIO JM, Fordyce M, Garner W, Vimal M, et al
    Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-uninfected Subjects with Severe Renal Impairment.
    Antimicrob Agents Chemother. 2016 May 23. pii: AAC.00005.
    PubMed     Text format     Abstract available


  109. VARGAS G, Vincent KL, Zhu Y, Szafron D, et al
    In vivo rectal mucosal barrier function imaging in a large animal model using confocal endomicroscopy: implications for injury assessment and use in HIV prevention studies.
    Antimicrob Agents Chemother. 2016 May 16. pii: AAC.00134.
    PubMed     Text format     Abstract available


  110. CHUNG DH, Golden JE, Adcock RS, Schroeder CE, et al
    Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state.
    Antimicrob Agents Chemother. 2016 May 16. pii: AAC.00282.
    PubMed     Text format     Abstract available


  111. WARRILOW AG, Parker JE, Price CL, Nes WD, et al
    The Investigational Drug VT-1129 is a Highly Potent Inhibitor of Cryptococcus species CYP51 but only Weakly Inhibits the Human Enzyme.
    Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00349.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: